Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;41(10):e15414.
doi: 10.1111/dme.15414. Epub 2024 Jul 24.

Insulin icodec: A novel once-weekly treatment for diabetes

Hannah Schaffner  1 , Jordyn Wiener  2 , Amanda DeLuca  2 , Ariana Genovese  3 , Alexander Deeb  4 , Wasim Deeb  5 , Mae Sheikh-Ali  6 , David Sutton  6 , Ashwini Gore  7 , Jason Berner  8 , Jessica Huston  2 , Rebecca Goldfaden  1
Affiliations
Review

Insulin icodec: A novel once-weekly treatment for diabetes

Hannah Schaffner et al. Diabet Med. 2024 Oct.

Abstract

Aims: To summarize the results of clinical studies of insulin icodec, an investigational insulin analog designed for once-weekly administration, in adults with type 1 and type 2 diabetes.

Methods: Thirteen published articles describing clinical studies of insulin icodec were identified in PubMed, and data pertinent to key study outcomes were selected for inclusion in this review.

Results: In insulin-naïve and insulin-treated individuals, icodec demonstrated efficacy in glycaemic control superior or noninferior to that of insulins glargine U100, glargine U300 and degludec. Icodec exhibited a safety profile comparable to marketed insulins, with the exception of hypoglycaemic event rates.

Conclusions: As a once-weekly alternative to daily basal insulin, icodec is expected to improve patient adherence and satisfaction, reducing the required number of injections per year from 365 to 52 and providing a dosing option potentially attractive to a wide range of insulin users. However, clinical data suggest a notable risk of hypoglycaemia with weekly icodec administration, especially in individuals with type 1 diabetes.

Keywords: diabetes; diabetes mellitus; diabetes mellitus, type 1; diabetes mellitus, type 2; insulin; insulin, long‐acting.

PubMed Disclaimer

References

REFERENCES

    1. Kjeldsen TB, Hubálek F, Hjørringgaard CU, et al. Molecular engineering of insulin ICODEC, the first acylated insulin analog for once‐weekly administration in humans. J Med Chem. 2021;64(13):8942‐8950.
    1. Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once‐weekly dosing. BMJ Open Diabetes Res Care. 2021;9(1):1‐10.
    1. Pieber T, Asong M, Fluhr G, et al. Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes. Diabetes Obes Metab. 2023;25:3716‐3723.
    1. Hövelmann U, Engberg S, Heise T, et al. Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes. Diabetes Obes Metab. 2024;26:1941‐1949.
    1. Rosenstock J, Bajaj HS, Janež A, et al. One‐weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107‐2116.

MeSH terms

Grants and funding